We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in China

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00478829
First Posted: May 25, 2007
Last Update Posted: December 6, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Wyeth is now a wholly owned subsidiary of Pfizer
  Purpose

Objectives: Primary: To estimate the prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings in China.

Secondary:

  • To estimate gender- and age-specific prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings in China.
  • To estimate the prevalence of depression and/or anxiety disorder in outpatients attending the general health care settings such as departments of neurology, gastroenterology, cardiology, and gynecology.
  • To describe the recognition and treatment rate by treating physicians as depression and/or anxiety for outpatients in the general health care settings in China.

Condition
Adult

Study Type: Observational
Study Design: Time Perspective: Prospective
Official Title: Prevalence of Depression and Anxiety in Patients Seeking Medical Care at General Health Care Settings in 5 Large Cities in China

Resource links provided by NLM:


Further study details as provided by Wyeth is now a wholly owned subsidiary of Pfizer:

Estimated Enrollment: 8000
Study Start Date: April 2007
Study Completion Date: July 2007
Detailed Description:
This study is designed to investigate the status of identifying depression and/or anxiety disorder with somatic symptoms in general hospitals in China. The study will generate valuable information to the medical community; therefore the early and vigorous treatment is possible. It's in line with China government authorities' target to increase the recognition rate of depression and/or anxiety in primary care settings to more than 50% by the end of 2010. The study will also help to identify specific diagnosis and treatment patterns for depressive / anxious patients and their comorbid conditions.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Main Inclusion Criteria:

  • Greater than or equal to 18 years.
  • Consecutive general internal medical outpatients attending the selected general hospitals in the investigate days(Department of neurology, gastrointestinal, cardiology and gynecology).
  • Informed consent obtained for all patients who will undergo a standardized diagnostic assessment by specialized psychiatrists.

Main Exclusion Criteria:

  • Patients who have been screened on a previous visit.
  • Patients who are unable to complete the survey because of mental or physical incapacity.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00478829


Locations
China, Beijing
Beijing, Beijing, China, 100034
Beijing, Beijing, China, 100044
Beijing, Beijing, China, 100730
China, Guangdong
Guangzhou, Guangdong, China, 510120
Guangzhou, Guangdong, China, 510180
Guangzhou, Guangdong, China, 510630
China, Hunan
Changsha, Hunan, China, 410008
Changsha, Hunan, China, 410011
Changsha, Hunan, China, 410013
China, Shanghai
Shanghai, Shanghai, China, 200025
Shanghai, Shanghai, China, 200233
Shanghai, Shanghai, China, 200235
China, Sichuan
Chengdu, Sichuan, China, 610041
Chengdu, Sichuan, China, 610072
Chengdu, Sichuan, China, 610083
Sponsors and Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Medical Monitor Wyeth is now a wholly owned subsidiary of Pfizer
Principal Investigator: Trial Manager For China, medinfo@wyeth.com
  More Information

ClinicalTrials.gov Identifier: NCT00478829     History of Changes
Other Study ID Numbers: 0600B2-4417
First Submitted: May 24, 2007
First Posted: May 25, 2007
Last Update Posted: December 6, 2007
Last Verified: December 2007

Additional relevant MeSH terms:
Depression
Behavioral Symptoms